Blinatumomab in Relapsed/Refractory Burkitt Lymphoma

SIMPLE SUMMARY: 20–40% of patients with Burkitt lymphoma (BL) have relapsing or refractory (r/r) disease, and standard treatment for such patients is poorly established. An unexplored treatment option is the bispecific T-cell engager blinatumomab, as used for the treatment of r/r and minimal residua...

Descripción completa

Detalles Bibliográficos
Autores principales: Bohler, Jeanne, Bacher, Ulrike, Banz, Yara, Stadelmann, Raphael, Medinger, Michael, Zander, Thilo, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817963/
https://www.ncbi.nlm.nih.gov/pubmed/36612039
http://dx.doi.org/10.3390/cancers15010044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817963/
https://www.ncbi.nlm.nih.gov/pubmed/36612039
http://dx.doi.org/10.3390/cancers15010044

Ejemplares similares